Cangrelor

In cardiology, cangrelor is an purinergic P2Y receptor antagonists that is a platelet aggregation inhibitor.

History
Cangrelor has not been approved for use in the United States by the Food and Drug Administration

Toxicity
Drug toxicity include

Drug interactions
Drug interactions include

Clinical use
Cangrelor has been studied in several major randomized controlled trials:
 * CHAMPION PHOENIX "Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding" according to a randomized controlled trial. In this study of 11,145 patients who were undergoing either urgent or elective percutaneous transluminal coronary angioplasty, the relative risk ratio of cangrelor infusion compared to clopidogrel 600 mg or 300 mg oral bolus for composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization was 0.8 and the relative risk reduction was 20.3%. In populations similar to those in this study which had a rate of risk as measured by the composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization of 5.9% without treatment, the number needed to treat is 83.
 * CHAMPION PLATFORM "The use of periprocedural cangrelor during PCI was not superior to placebo in reducing the primary end point" according to a randomized controlled trial. In this study of 5362 patients undergoing either urgent percutaneous transluminal coronary angioplasty, the relative risk ratio of cangrelor infusion compared to placebo for composite of death, myocardial infarction, or ischemia-driven revascularization at 48 hours was 0.9 and the relative risk reduction was 12.5%. In populations similar to those in this study which had a rate of risk as measured by the composite of death, myocardial infarction, or ischemia-driven revascularization at 48 hours of 8% without treatment, the number needed to treat is 100.